Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | PTGIR | P43119 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.36 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.36 |
| ▸ | TRPC6 | Q9Y210 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4234325 | 0.93 | ACHE (0.41) | ACHEPTGIRPOLBL3MBTL1KMT2A | |
| SCHEMBL4240130 | 0.90 | ACHE (0.38) | ACHEPTGIRPOLBL3MBTL1KMT2A | |
| SCHEMBL4233438 | 0.85 | ACHE (0.37) | ACHEPTGIRPOLBL3MBTL1 | |
| SCHEMBL4686937 | 0.82 | POLB (0.43) | ACHEPTGIRPOLBKMT2AMAPT | |
| SCHEMBL4233453 | 0.80 | ACHE (0.39) | ACHEPTGIRKMT2AMEN1MAPT | |
| SCHEMBL4229108 | 0.79 | MCHR1 (0.36) | ACHEPTGIRPOLBL3MBTL1KMT2A | |
| SCHEMBL13699157 | 0.75 | CHRM1 (0.44) | PTGIRKMT2ALPAR1LPAR5 | |
| SCHEMBL4226943 | 0.74 | ACHE (0.35) | ACHEPTGIRPOLBLPAR1LPAR5 | |
| SCHEMBL4240156 | 0.72 | MCHR1 (0.39) | PTGIRPOLBKDM4E | |
| SCHEMBL4233632 | 0.71 | ABCG2 (0.45) | KMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | ACHE 560/4885PTGIR 526/4885POLB 4249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.